건강한 남성 지원자를 대상으로 한 기술 변경 전후의 EnliTuo® 비교 연구
건강한 남성 자원자를 대상으로 기술 변경 전후의 EnliTuo® 약동학, 안전성 및 면역원성 비교를 위한 무작위, 이중 맹검, 병렬-대조군, 단일 용량 연구
This study is a randomized, double-Blind, parallel-controlled, single-dose pharmacokinetic, safety, and immunogenicity comparative study of EnliTuo® before and after technology change in healthy male volunteers.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Shanghai, 중국
- Shanghai Xuhui Central Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Healthy males aged ≥ 18 years and ≤ 45 years on the day of signing the informed consent form;
- At screening, body weight ≥ 50 kg and ≤ 80 kg, with a Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive of boundary values);
- Capable of understanding the study, including its purpose, research procedures, potential risks, etc., and able to communicate well with researchers and complete the study in accordance with the study requirements;
- Voluntarily sign the informed consent form.
Exclusion Criteria:
- Subjects with any abnormally clinically significant findings in comprehensive examinations (vital signs, physical examination, electrocardiogram, chest X-ray, abdominal ultrasound, blood routine, urine routine, blood biochemistry, coagulation, etc.) as judged by the investigator;
- Subjects with a history of major diseases in the cardiovascular, endocrine, nervous, digestive, respiratory, genitourinary, hematological, immune, or mental systems, or currently suffering from any disease in the above systems;
- Subjects with a known or suspected history of keratitis, ulcerative keratitis, conjunctivitis, blepharitis, or severe dry eye;
- Subjects with hereditary bleeding tendency, coagulation dysfunction, or a history of thrombotic or hemorrhagic diseases;
- Subjects with active infections requiring systemic treatment;
- Subjects positive for any of HBV surface antigen, HCV antibody, HIV antibody, or Treponema pallidum antibody;
- Subjects with a history of malignant tumors within the past 5 years, except for completely resected in-situ cutaneous basal cell carcinoma or squamous cell carcinoma;
- Subjects who have undergone surgical operations within 4 weeks before screening, or plan to undergo surgery during the trial period;
- Subjects who have used any prescription drugs, over-the-counter drugs, traditional Chinese medicines, proprietary Chinese medicines, health supplements, etc., within 4 weeks before screening, or whose use of the above substances has not exceeded 5 half-lives (whichever is longer);
- Subjects who have used any biological products or received any vaccines within 12 weeks before screening, or plan to receive any vaccines during the study period;
- Subjects currently enrolled in other clinical studies of drugs or medical devices, or whose time since the end of the last enrolled clinical study is less than 12 weeks, or whose time since the last trial drug administration has not exceeded 5 half-lives (whichever is longer);
- Subjects positive for anti-drug antibodies against anti-epidermal growth factor receptor antibodies;
- Subjects with substance abuse, or who have used soft drugs within 3 months before screening or hard drugs within 1 year before screening; or who consume excessive tea, coffee, and/or caffeinated beverages daily (more than 8 cups, 1 cup = 250 mL); or who have a positive urine drug screen;
- Subjects with alcoholism, or whose weekly alcohol consumption exceeds 14 units within 3 months before screening (1 unit = 17.7 mL ethanol, i.e., 1 unit = 357 mL of beer with 5% alcohol content, 43 mL of liquor with 40% alcohol content, or 147 mL of wine with 12% alcohol content); or who have a positive alcohol breath test; and those who cannot cooperate with alcohol prohibition during the study;
- Subjects who smoked more than 10 cigarettes per day on average within 6 months before screening;
- Subjects who engaged in strenuous activities within 72 hours before drug administration, or cannot avoid strenuous activities during the study; or have other physiological or pathological conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug;
- Subjects who have donated blood (including component blood) or lost more than 400 mL of blood, or received blood transfusions within 3 months before screening; or donated blood (including component blood) or lost more than 200 mL of blood within 1 month before screening;
- Subjects with a known history of allergy to the active ingredient or any excipient of the study drug, or to other biological products; or with a history of atopic allergic diseases (e.g., asthma, urticaria, eczematous dermatitis, etc.); or with allergic diathesis;
- Subjects who cannot tolerate venipuncture or have a history of fainting due to needle or blood;
- Subjects with special dietary requirements who cannot accept the diet provided by the clinical trial center;
- Subjects who cannot take effective contraceptive measures or plan to donate sperm within 3 months after the administration of the study drug;
- Other conditions deemed by the investigator to make the subject unsuitable for participating in this study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: New technology Enlituo
treated with new technology Enlituo through single intravenous drip |
250 mg/m^2, single intravenous drip |
|
활성 비교기: Approved technology Enlituo
treated with Approved technology Enlituo through single intravenous drip |
250 mg/m^2, single intravenous drip |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
AUC0-∞
기간: From enrollment to the end of treatment at 28 days
|
Area under the concentration time curve extrapolated to infinity |
From enrollment to the end of treatment at 28 days
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
AUC0-t
기간: From enrollment to the end of treatment at 28 days
|
Area under the concentration time curve from time zero to the last measurable time point. |
From enrollment to the end of treatment at 28 days
|
|
Cmax
기간: From enrollment to the end of treatment at 28 days
|
Peak concentration. |
From enrollment to the end of treatment at 28 days
|
|
Tmax
기간: From enrollment to the end of treatment at 28 days
|
time to peak |
From enrollment to the end of treatment at 28 days
|
|
t1/2
기간: From enrollment to the end of treatment at 28 days
|
half-life |
From enrollment to the end of treatment at 28 days
|
|
λz
기간: From enrollment to the end of treatment at 28 days
|
Terminal Elimination Rate Constant |
From enrollment to the end of treatment at 28 days
|
|
CL
기간: From enrollment to the end of treatment at 28 days
|
clearance |
From enrollment to the end of treatment at 28 days
|
|
Vd
기간: From enrollment to the end of treatment at 28 days
|
volume of distribution |
From enrollment to the end of treatment at 28 days
|
|
Immunogenicity
기간: From enrollment to the end of treatment at 28 days
|
Anti-drug antibody positive rate |
From enrollment to the end of treatment at 28 days
|
|
Adverse Event
기간: From enrollment to the end of treatment at 6 months
|
Incidence and Severity of Adverse Events |
From enrollment to the end of treatment at 6 months
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Jingying Jia, PhD, Xuhui Central Hospital, Shanghai
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- CMAB009-C-102
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
After the study result is published, email the application registration contact or the study leader to obtain it.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .